Taurohyodeoxycholic acid protects against taurochenodeoxycholic acid-induced cholestasis in the rat.
The prevention of the hepatotoxic effects produced by intravenous infusion of taurochenodeoxycholic acid (TCDCA) by coinfusion with taurohyodeoxycholic acid (THDCA) was evaluated in bile fistula rats; the hepatoprotective effects of the latter were also compared with those of tauroursodeoxycholic acid (TUDCA). Rats infused with TCDCA at a dose of 8 micromol/min/kg showed reduced bile flow and calcium secretion, as well as increased biliary release of alkaline phosphatase (AP) and lactate dehydrogenase (LDH). This was associated with a very low biliary secretion rate of TCDCA (approximately 1 micromol/min/kg). Simultaneous infusion of THDCA or TUDCA at the same dose preserved bile flow and almost totally abolished the pathological leakage of the two enzymes into bile. The effect was slightly more potent for THDCA. The maximum secretion rate of TCDCA increased to the highest value (8 micromol/min/kg) when coinfused with either of the two hepatoprotective bile acids (BA), which were efficiently and completely secreted in the bile, without metabolism. Calcium output was also restored and phospholipid (PL) secretion increased with respect to the control saline infusion. This increase was higher in the THDCA study. These data show that THDCA is highly effective in the prevention of hepatotoxicity induced by intravenous infusion of TCDCA by facilitating its biliary secretion and reducing its hepatic residence time; this was associated with selective stimulation of PL biliary secretion.
Roda
A
A
Department of Pharmaceutical Sciences, University of Bologna, Italy.
Piazza
F
F
Baraldini
M
M
Speroni
E
E
Guerra
M C
MC
Cerré
C
C
Cantelli Forti
G
G
D000469:Alkaline Phosphatase / Q000032:analysis; D000818:Animals; D002118:Calcium / Q000032:analysis; D002756:Cholagogues and Choleretics / Q000008:administration & dosage / Q000032:analysis / Q000737:chemistry / Q000494:pharmacology*; D002779:Cholestasis / Q000139:chemically induced / Q000517:prevention & control*; D007275:Injections, Intravenous; D007770:L-Lactate Dehydrogenase / Q000032:analysis; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D010743:Phospholipids / Q000032:analysis; D051381:Rats; D013655:Taurochenodeoxycholic Acid / Q000032:analysis / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000494:pharmacology; D013656:Taurocholic Acid / Q000737:chemistry; D013657:Taurodeoxycholic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000032:analysis / Q000737:chemistry / Q000494:pharmacology
D002756:Cholagogues and Choleretics; D010743:Phospholipids; C083510:taurohyodeoxycholic acid; D013655:Taurochenodeoxycholic Acid; D013657:Taurodeoxycholic Acid; D013656:Taurocholic Acid; C031655:ursodoxicoltaurine; D007770:L-Lactate Dehydrogenase; D000469:Alkaline Phosphatase; D002118:Calcium